Story · Medicine & Biotech

David Aggen: Adjuvant Therapy Initiation and Completion Rates Differ Across Phase III Trials

1 outlet · first reported by OncoDaily on

David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Adjuvant therapy initiation and completion rates differ amongst phase III trials. If you start EV/P neoadjuvant then (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study randomized trial
    David Aggen: Adjuvant Therapy Initiation and Completion Rates Differ Across Phase III Trials

    David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Adjuvant therapy initiation and completion rates differ amongst phase III trials. If you start EV/P neoadjuvant then

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.